Zydus Gets USFDA approval For Oxybutynin Chloride Extended-Release Tablets


Zydus Cadila has received the final approval from the USFDA to market Oxybutynin Chloride Extended-Release Tablets in the strengths of 5 mg, 10 mg and 15 mg.

The drug is used to treat symptoms of overactive bladder and urine leakage. It will be manufactured at the group’s manufacturing facility at Moraiya in Ahmedabad.

Meanwhile, Cadila Healthcare was trading higher by 0.1% at Rs 526.05 per share at 1023 hours on BSE. It hit a high of Rs 532.20 and a low of Rs 524.05 so far during the morning session.

The stock has delivered more than 60% returns in a period of one year. It has outperformed both BSE Sensex and BSE Healthcare over a period of one year. Its closest peers are Lupin and Sun Pharmaceutical Industries.

Cadila Healthcare Limited, an integrated healthcare company, discovers, develops, manufactures, and markets a range of healthcare and pharmaceutical products worldwide.

For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔

Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: